ARLN and osteoporosis: ALN, a traditional anti-osteoporosis drug witha high affinityfor the bone surface,43 was used for bone-targeteddelivery to increase the local DHA concentration in the bone microenvironments.We labeled the MSN-ALN and the MSN-PEG with rhodamine to confirm thebone-targeting efficacy of ALN and determined the fluorescence intensitydistribution at 1 h, 1 day, 4 days, and 7 days after intravenous injection.44 Caliper IVIS Lumina analogue images demonstratedthat there were no significant differences in the fluorescence signaldistribution at 1 h and 1 day postinjection.